| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3065489 | Journal of Neuroimmunology | 2007 | 9 Pages |
Abstract
Anti-IFNβ antibodies are related to IFNβ bioavailability loss in multiple sclerosis. We investigated the reliability of radioimmunoprecipitation and cytopathic assays in detecting binding (BAbs) and neutralizing (NAbs) antibodies and the correlation of these antibodies to MxA mRNA production. Eleven percent of IFNβ-treated patients showed a lack of MxA induction, with an inverse correlation between MxA mRNA and the presence of BAbs and NAbs. Some patients had contemporary MxA induction in the presence of high NAb titres, thus calling into question the reliability of cytopathic assay. Since anti-IFNβ antibodies well correlated with MxA induction loss, MxA assay is an appropriate test to determine IFNβ bioavailability.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Ruggero Capra, Alessandra Sottini, Cinzia Cordioli, Federico Serana, Marco Chiarini, Luigi Caimi, Alessandro Padovani, Roberto Bergamaschi, Luisa Imberti,